Shares of ResMed Inc. RMD slid 3.83% to $205.17 Friday, on what proved to be an all-around dismal trading session for the ...

StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...

The home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea ...

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...

BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...

RMD recently launched its home sleep apnea test, NightOwl, across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT), designed to offer healthcare providers a simplified, ...

Resmed (RMD) announced its home sleep apnea test, NightOwl, is now available across the United States. NightOwl is an FDA-cleared home sleep ...

We recently published a list of Jim Cramer Recently Talked About These 12 Companies. In this article, we are going to take a ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...

ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.